Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Oct;10(10):758-62.
doi: 10.1097/GIM.0b013e318183722f.

Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease

Roddy McDowell  1 , Jennifer S Li, Daniel Kelly Benjamin Jr, Claire Morgan, Alison Becker, Priya S Kishnani, Ronald J Kanter
Affiliations
Clinical Trial

Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease

Roddy McDowell et al. Genet Med. 2008 Oct.

Abstract

Purpose: Enzyme replacement therapy in infants with Pompe disease prolongs survival, decreases cardiomegaly, and improves muscle function. Because ectopy has been previously described in these patients, we sought to determine the prevalence and types of arrhythmias.

Methods: Thirty-eight children with infantile Pompe disease received enzyme replacement therapy in two open-label, multicenter, international, clinical trials. Data were reviewed on a retrospective basis. The corrected QT interval, ejection fraction, and indexed left ventricular mass were measured on a scheduled basis from electrocardiograms and echocardiograms. Arrhythmias were identified and characterized from electrocardiograms, ambulatory electrocardiograms, and point-of-care monitoring. Electrocardiogram and echocardiogram measurements were compared in children with and without arrhythmias.

Results: Seven children (18%) experienced arrhythmias. The QT interval, ejection fraction, indexed left ventricular mass, and rate of reduction of indexed left ventricular mass were not statistically different in those seven versus the other 31 children. Two children with life-threatening arrhythmias had among the highest combined baseline maximum indexed left ventricular mass and QT interval. Their arrhythmias occurred during severe metabolic stress from noncardiac illness.

Conclusions: There was a high incidence of arrhythmias in our cohort. The relationship of arrhythmias with enzyme replacement therapy, myocardial fibrosis, or simply longer survival is unknown. Therefore, further characterization of specific arrhythmia risk factors and continued vigilance regarding screening for arrhythmias in children receiving enzyme replacement therapy is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Combined maximum QTc and maximum LVMi for each patient by arrhythmia category. Circle, no arrhythmia; diamond, possibly clinically important; triangle, definitely clinically important; square, life-threatening.
See this image and copyright information in PMC

References

    1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144:S35–S43. - PubMed
    1. Hirshhorn R. Glycogen storage disease type ii: Acid alpha-glucosidase deficiency. McGraw Hill; New York: 2001.
    1. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset pompe disease. J Pediatr. 2006;148:671–676. - PubMed
    1. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT. The natural course of infantile pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332–340. - PubMed
    1. Bharati S, Serratto M, DuBrow I, Paul MH, Swiryn S, Miller RA, Rosen K, Lev M. The conduction system in pompe's disease. Pediatr Cardiol. 1982;2:25–32. - PubMed

Publication types